Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alnylam Pharmaceuticals (NQ: ALNY )

146.41 -0.95 (-0.64%)
Streaming Delayed Price Updated: 12:13 PM EDT, Apr 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 108,737
Open 146.07
Bid (Size) 146.21 (4)
Ask (Size) 146.66 (4)
Prev. Close 147.36
Today's Range 145.42 - 148.05
52wk Range 141.97 - 218.88
Shares Outstanding 118,847,693
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
How Is The Market Feeling About Alnylam Pharmaceuticals?
Via Benzinga
Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results
From Alnylam Pharmaceuticals, Inc.
Via Business Wire

Performance

YTD
-24.89%
-24.89%
1 Month
-4.51%
-4.51%
3 Month
-19.09%
-19.09%
6 Month
-3.30%
-3.30%
1 Year
-27.47%
-27.47%

More News

Read More
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Analysts Express Confidence in Alnylam's Hypertension Drug Despite Mixed Trial Data
Via Benzinga
Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
$100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today
Via Benzinga
Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback
Via Investor's Business Daily
Exposures Product Safety
3 Biotech Stocks to Buy on the Dip: March 2024
Via InvestorPlace
Alnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific Session
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Earnings Scheduled For February 15, 2024
Via Benzinga
Alnylam Pharmaceuticals's Earnings Outlook
Via Benzinga
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 15 Years
Via Benzinga
Billionaire’s Biotech Bets: 3 Stocks Dominating Bill Gates’ Portfolio
Via InvestorPlace
Alnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive Disease
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Pharma Stock Roundup: Novo Nordisk's New Obesity Pill Data, Roche, AstraZeneca's Pipeline Updates
Via Talk Markets
Exposures Product Safety
Roche/Alnylam Blood Pressure Drug Aces In Mid-Stage Trial, Analyst Says Zilebesiran As Promising Opportunity In Addressing Global Hypertension Challenges
Via Benzinga
Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Here's How Much $100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth Today
Via Benzinga
Alnylam to Webcast Presentations at Upcoming March Investor Conferences
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Weight-Loss Drugs Have One Big Problem. These Drugmakers Are Taking It On.
Via Investor's Business Daily
Goldman Sachs Downgrades Alnylam Pharmaceuticals: Here's What You Need To Know
Via Benzinga
Why Is Alnylam Pharmaceuticals Stock Trading Lower On Thursday?
Via Benzinga
Exposures Product Safety
Why Alnylam Pharmaceuticals Stock Is Sinking Today
Via The Motley Fool
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Period Activity
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.